Amplitude VenturesReverb Therapeutics — Redirecting endogenous cytokinesLaunching Reverb Therapeutics out of stealth mode to redirect endogenous cytokines using antibodies3 min read·Nov 15, 2023----
Amplitude VenturesTentarix — creating next-generation multi-functional biologicsAnnouncing our lead investment into a $35M Series B financing of antibody developer Tentarix4 min read·Sep 6, 2023----
Amplitude VenturesEvommune — bringing new immunology medicines to patientsAnnouncing $50M US Series B Round to advance several therapies to treat chronic immune diseases6 min read·Apr 26, 2023----
Amplitude VenturesRadiant BioTherapeutics — utilizing multabodies to transform antibody therapeuticsAnnouncing Radiant Biotherapeutics emerging out of stealth mode with $8M Seed Round and Two Pharma Partnerships5 min read·Apr 25, 2023----
Amplitude VenturesAbdera Therapeutics: utilizing radiopharmaceuticals to revolutionize cancer treatmentThe announcement of a $142M USD Series A + B Financing5 min read·Apr 20, 2023----
Amplitude VenturesDrugbank — scaling the world’s-leading online drug databaseClosing of a $9M oversubscribed seed round for Drugbank5 min read·Apr 11, 2022----
Amplitude VenturesinAmplitude VCCelsius Therapeutics: bringing further precision to precision medicine — the promise of…Celsius Therapeutics announcing an additional $83M USD in financing and the promise of single cell genomics4 min read·Mar 28, 2022----
Amplitude VenturesinAmplitude VCCelebrating International Day of Women and Girls in ScienceMeet the wonderful women who are leading action and innovation at our firm and in our portfolio8 min read·Feb 11, 2022----
Amplitude VenturesinAmplitude VCCongruence Therapeutics — The AI platform targeting protein misfoldingCongruence Therapeutics $50M Series A — announcing Clarissa Desjardins’ new company5 min read·Feb 8, 2022----
Amplitude VenturesinAmplitude VCGandeeva Therapeutics — unlocking the power of cryo-EMGandeeva Therapeutics $40M Series A Financing — why we’re excited5 min read·Jan 31, 2022----
